From Name

From Email

To Name

To Email

Message

FDA grants new indication for tecentriq plus cotellic and zelboraf for advanced melanoma

from Pharmacy Practice News

FDA grants new indication for tecentriq plus cotellic and zelboraf for advanced melanoma Pharmacy Practice News The FDA granted a new indication for atezolizumab to be used with cobimetinib and vemurafenib to treat patients with BRAF V600 mutation-positive advanced melanoma. The supplemental Biologics License Application for atezolizumab was based on results from the phase 3 IMspire150 study, a multicenter, double-blind, placebo-controlled, randomized study in people with previously untreated BRAF V600 mutation–positive metastatic or unresectable locally advanced melanoma. READ MORE

more